Andrés Lanzós
Andrés Lanzós
Data Scientist at Biognosys
Verified email at - Homepage
Cited by
Cited by
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
E Rheinbay, MM Nielsen, F Abascal, JA Wala, O Shapira, G Tiao, ...
Nature 578 (7793), 102-111, 2020
Hacking the cancer genome: profiling therapeutically actionable long non-coding RNAs using CRISPR-Cas9 screening
R Esposito, N Bosch, A Lanzós, T Polidori, C Pulido-Quetglas, R Johnson
Cancer cell 35 (4), 545-557, 2019
Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis
J Carlevaro-Fita, A Lanzós, L Feuerbach, C Hong, D Mas-Ponte, ...
Communications Biology 3 (1), 1-16, 2020
Discovery of Cancer Driver Long Noncoding RNAs across 1112 Tumour Genomes: New Candidates and Distinguishing Features
A Lanzós, J Carlevaro-Fita, L Mularoni, F Reverter, E Palumbo, R Guigó, ...
Scientific Reports. 2017; 7: 41544, 2017
Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs
A Vancura, A Lanzós, N Bosch-Guiteras, MT Esteban, AH Gutierrez, ...
NAR Cancer 3 (2), zcab013, 2021
EACR Cancer Genomics 2019 conference: from tumour evolution to personalised immunotherapy
A Lanzós, K Elliott
The FEBS journal, 2019
Identifying novel biomarkers with deep proteomics profiling and survival analysis in NSCLC patients treated with anti-PD-1-blockade
E Nguyen, R Poli, K Sklodowski, V Dozio, A Lanzós, K Beeler, E Romano
Annals of Oncology 32, S1382, 2021
Tumour mutations in long noncoding RNAs that enhance cell fitness
R Esposito, A Lanzós, T Polidori, H Guillen-Ramirez, B Merlin, L Mela, ...
Big Proteomic Data from a Digital Biobank Boost the Confidence in Biomarker Discovery
A Lanzós, R Bruderer, J Muntel, L Reiter, O Rinner, S Schegk
ASMS 2021, 2021
Immune-related adverse effects (irAEs) associated proteomic profile in late-stage NSCLC patients after PD-1 blockade
K Sklodowski, V Dozio, R Poli, A Lanzós, S Lopez-Lastra, K Beeler, ...
Cancer Research 81 (13_Supplement), 1615-1615, 2021
Protein signature associated with response and progression free survival in late-stage NSCLC patients treated with anti-PD-1 blockade
E Romano, K Sklodowski, V Dozio, A Lanzós, K Beeler
Annals of Oncology 32, S12, 2021
Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities
R Esposito, T Polidori, D Meise, C Pulido, P Chouvardas, S Forster, ...
bioRxiv, 2021
Integrating deep proteomics profiling with survival analysis to identify novel biomarkers of response to PD-1 blockade in NSCLC patients
K Sklodowski, V Dozio, S Lopez-Lastra, A Lanzós, K Beeler, E Romano
Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020
The system can't perform the operation now. Try again later.
Articles 1–13